Molecular Partners Ag (MOLN) Tax Provisions (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Tax Provisions of $7.15 for Q1 2026, up 221.48% year-over-year from $2.22 in Q1 2025, and down 99.71% quarter-over-quarter from $2495.3 in Q4 2025.
Molecular Partners Ag (MOLN) Tax Provisions (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Tax Provisions for 7 consecutive years, with $7.15 the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions rose 221.48% year-over-year to $7.15; the TTM figure through Mar 2026 stood at $2516.2 (up 10.1% YoY), while the FY2025 annual figure was $2502.3, up 9.61% from the prior year.
- Tax Provisions retreated to $7.15 in Q1 2026 per MOLN's latest filing, from $2495.3 in the prior quarter.
- Across five years, Tax Provisions topped out at $2495.3 in Q4 2025 and bottomed at -$12.85 in Q4 2023.
- Historically, Tax Provisions has averaged $320.54 across 5 years, with a median of $6.45 in 2023.
- Annual changes were most pronounced in 2023 — Tax Provisions sank 113.47% — and 2024, when it jumped 17813.7%.
- Molecular Partners Ag's Tax Provisions stood at -$6.02 in 2022, then tumbled by 113.47% to -$12.85 in 2023, then surged by 17813.7% to $2276.5 in 2024, then advanced by 9.61% to $2495.3 in 2025, then tumbled by 99.71% to $7.15 in 2026.
- Business Quant data shows MOLN's Tax Provisions at $7.15 in Q1 2026, $2495.3 in Q4 2025, and $7.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | - |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 7.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.15 |
| Dec 31, 2025 | 2,495.33 |
| Sep 30, 2025 | 7.00 |
| Jun 30, 2025 | 6.76 |
| Mar 31, 2025 | 2.22 |
| Dec 31, 2024 | 2,276.54 |
| Sep 30, 2024 | 6.58 |
| Mar 31, 2024 | 6.53 |
| Dec 31, 2023 | -12.85 |
| Sep 30, 2023 | 6.45 |
| Mar 31, 2023 | 6.16 |
| Dec 31, 2022 | -6.02 |
| Sep 30, 2022 | 6.01 |
| Jun 30, 2022 | -6.02 |
| Mar 31, 2022 | 6.28 |
| Dec 31, 2021 | 2,163.47 |
| Sep 30, 2021 | 5.55 |
| Dec 31, 2020 | -12,179.88 |
| Sep 30, 2020 | 26.07 |